Vancouver, B.C. and Boston, MA, October 2, 2018 – Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) announced that Steven Chan has resigned from its Board of Directors for personal reasons and Chris Bleck has been appointed as Mr. Chan’s successor, effective immediately.
“On behalf of everyone at Imagin, I would like to thank Steven for his many contributions to the Company,” said Robin A. Atlas, M.D., Chairperson of Imagin’s Board of Directors. “I am also very pleased to welcome Chris to our team. He has extensive executive leadership experience, playing a critical role in developing corporate strategy and managing operations for both emerging and large companies in the global healthcare industry.”
“The recent submission of a pre-submission package marked the initiation of the FDA process for Imagin’s i/Blue Imaging System, and Chris’ diverse background working with companies in the medical device, diagnostic, nutrition and pharmaceutical industries should prove to be a tremendous asset to our Board and to our shareholders as we move forward,” added Dr. Atlas.
Mr. Bleck is an accomplished global healthcare industry veteran with over three decades of experience, including leading or being integrally involved with multiple clinical development programs, commercial product launches, public financings, licensing transactions, and mergers and acquisitions. Most recently, he served as the Chief Operating Officer for OvaScience, a life science company focused on the discovery and development of novel treatments for infertility. His earlier experience includes senior management roles with Cytyc Corporation (now Hologic, Inc.), Intact Medical Corporation (acquired by Medtronic plc) and Incept BioSystems, Inc. (acquired by ORIGIO a/s). Mr. Bleck began his career at Abbot Laboratories, where he held progressive positions over 18 years, including Corporate Vice President of Pediatric Products and President of Abbott Canada. Mr. Bleck holds a B.S. in Pharmacy and an M.B.A. from the University of Connecticut.
About Imagin Medical
Imagin is developing powerful new imaging solutions for the detection and visualization of cancer. The Company believes its technology will radically improve cancer care during minimally invasive procedures, improving the surgeon’s ability to visualize, identify and remove cancerous cells. Imagin’s initial target market is bladder cancer, the sixth most common cancer in the U.S., and the costliest cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, Imagin’s advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imagindev.wpengine.com.
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
Contacts:
Stephen Kilmer
Investor Relations
Telephone: 647-872-4849
Email: [email protected]
